Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial

Abstract

This randomized, double-blind, placebo-controlled, multi-center study investigated the clinical efficacy of two probiotic strains on abdominal pain severity and symptomology in irritable bowel syndrome (IBS). Three hundred and thirty adults, aged 18 to 70 years, with IBS according to Rome IV criteria were allocated (1:1:1) to receive placebo, Lactobacillus acidophilus DDS-1 (1 × 1010 CFU/day) or Bifidobacterium animalis subsp. lactis UABla-12 (1 × 1010 CFU/day) over six weeks. The primary outcome was the change in Abdominal Pain Severity - Numeric Rating Scale (APS-NRS). Over the intervention period, APS-NRS was significantly improved in both probiotic groups vs. placebo in absolute terms (DDS-1: −2.59 ± 2.07, p = 0.001; UABla-12: −1.56 ± 1.83, p = 0.001) and in percentage of significant responders (DDS-1: 52.3%, p < 0.001); UABla-12 (28.2%, p = 0.031). Significant amelioration vs. placebo was observed in IBS Symptom Severity Scale (IBS-SSS) scores for L. acidophilus DDS-1 (−133.4 ± 95.19, p < 0.001) and B. lactis UABla-12 (−104.5 ± 96.08, p < 0.001) groups, including sub-scores related to abdominal pain, abdominal distension, bowel habits and quality of life. Additionally, a significant normalization was observed in stool consistency in both probiotic groups over time and as compared to placebo. In conclusion, L. acidophilus DDS-1 and B. lactis UABla-12 improved abdominal pain and symptom severity scores with a corresponding normalization of bowel habits in adults with IBS.

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

“…The literature search identified 4111 citations, of which 46 appeared to be relevant, and 17 were eligible and were incorporated into this guideline. [164][165][166][167][168][169][170][171][172][173][174][175][176][177][178][179][180] Fourteen of these were used to update meta-analyses. [164][165][166][167][168][169][170][171][172][173][174][175][176][177] Agreement between reviewers for study eligibility was excellent (kappa statistic=0.81).…”

“…[164][165][166][167][168][169][170][171][172][173][174][175][176][177][178][179][180] Fourteen of these were used to update meta-analyses. [164][165][166][167][168][169][170][171][172][173][174][175][176][177] Agreement between reviewers for study eligibility was excellent (kappa statistic=0.81). Of these 14 studies, 2 compared linaclotide with placebo, 164 165 and were used to update a previous network meta-analysis, 155 8 compared various probiotics with placebo, [166][167][168][169][170][171][172][173] and were used to update an existing trial-based meta-analysis 158 and 4 were RCTs of a low FODMAP diet, [174][175][176][177] and again were used to update a prior trial-based meta-analysis.…”

“…[164][165][166][167][168][169][170][171][172][173][174][175][176][177] Agreement between reviewers for study eligibility was excellent (kappa statistic=0.81). Of these 14 studies, 2 compared linaclotide with placebo, 164 165 and were used to update a previous network meta-analysis, 155 8 compared various probiotics with placebo, [166][167][168][169][170][171][172][173] and were used to update an existing trial-based meta-analysis 158 and 4 were RCTs of a low FODMAP diet, [174][175][176][177] and again were used to update a prior trial-based meta-analysis. 161 The remaining 3 RCTs were an 8-week trial of bimodal release ondansetron in IBS-D, 178 and 2 phase II trials of minesapride 179 180 a novel 5-HT 4 receptor agonist.…”

Probiotics, Anticipation Stress, and the Acute Immune Response to Night Shift

“…lactis UABla-12, on indices of the immune system in individuals undertaking night shift work. L. acidophilus DDS‐1 and B. lactis UABla-12, alone or in combination, have previously been shown to reduce abdominal pain severity and symptomology in irritable bowel syndrome ( 21 ), normalize bowel habits in functional constipation ( 22 ), provide abdominal symptom relief in lactose intolerance ( 23 ) and demonstrate an immune regulatory role in atopic dermatitis ( 24 ) and respiratory tract infection ( 25 ) in randomized controlled trials.…”

Chang-Kang-Fang Ameliorates Experimental Diarrhea Predominant Irritable Bowel Syndrome by Regulating Gut Microbiota and Gut -Brain Axis

“…Furthermore, disturbed microbiota structure is linked to co-morbidities of IBS, such as anxiety, depression and migraine [12,13]. On clinical trials, Lactobacillus probiotics [14,15] and multispecies probiotics [16], which contains the SCFAs-producing bacteria, have shown improvement symptoms in IBS patients. Targeting the gut microbiota may be a new treatment of IBS.…”